Silverfin false false 31/12/2025 01/01/2025 31/12/2025 Susan Jane Bell 19/11/2025 Dr Glenn Crocker 14/03/2024 Dr Joseph Henry Hedley 02/03/2021 Martlet Capital Directors Limited 20/08/2025 30/09/2024 Iain Alasdair Keith Moodie 19/11/2025 Dr Andrew Robert Pike 20/08/2025 06/06/2012 Rebecca Jane Roberts 20/08/2025 Carl Andrew Sterritt 29/10/2025 09/09/2024 Dr Eimer Mary Tuite 20/08/2025 06/06/2012 Christopher Mark Wheatcroft 20/08/2025 07/03/2023 23 April 2026 The principal activity of the Company was that of Synthetic DNA production. 08093593 2025-12-31 08093593 bus:Director1 2025-12-31 08093593 bus:Director2 2025-12-31 08093593 bus:Director3 2025-12-31 08093593 bus:Director4 2025-12-31 08093593 bus:Director5 2025-12-31 08093593 bus:Director6 2025-12-31 08093593 bus:Director7 2025-12-31 08093593 bus:Director8 2025-12-31 08093593 bus:Director9 2025-12-31 08093593 bus:Director10 2025-12-31 08093593 2024-12-31 08093593 core:CurrentFinancialInstruments 2025-12-31 08093593 core:CurrentFinancialInstruments 2024-12-31 08093593 core:Non-currentFinancialInstruments 2025-12-31 08093593 core:Non-currentFinancialInstruments 2024-12-31 08093593 core:ShareCapital 2025-12-31 08093593 core:ShareCapital 2024-12-31 08093593 core:SharePremium 2025-12-31 08093593 core:SharePremium 2024-12-31 08093593 core:RetainedEarningsAccumulatedLosses 2025-12-31 08093593 core:RetainedEarningsAccumulatedLosses 2024-12-31 08093593 core:OtherResidualIntangibleAssets 2024-12-31 08093593 core:OtherResidualIntangibleAssets 2025-12-31 08093593 core:OtherPropertyPlantEquipment 2024-12-31 08093593 core:OtherPropertyPlantEquipment 2025-12-31 08093593 2025-01-01 2025-12-31 08093593 bus:FilletedAccounts 2025-01-01 2025-12-31 08093593 bus:SmallEntities 2025-01-01 2025-12-31 08093593 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 08093593 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 08093593 bus:Director1 2025-01-01 2025-12-31 08093593 bus:Director2 2025-01-01 2025-12-31 08093593 bus:Director3 2025-01-01 2025-12-31 08093593 bus:Director4 2025-01-01 2025-12-31 08093593 bus:Director5 2025-01-01 2025-12-31 08093593 bus:Director6 2025-01-01 2025-12-31 08093593 bus:Director7 2025-01-01 2025-12-31 08093593 bus:Director8 2025-01-01 2025-12-31 08093593 bus:Director9 2025-01-01 2025-12-31 08093593 bus:Director10 2025-01-01 2025-12-31 08093593 core:OtherResidualIntangibleAssets core:TopRangeValue 2025-01-01 2025-12-31 08093593 core:PatentsTrademarksLicencesConcessionsSimilar 2025-01-01 2025-12-31 08093593 core:OtherPropertyPlantEquipment 2025-01-01 2025-12-31 08093593 2024-01-01 2024-12-31 08093593 core:OtherResidualIntangibleAssets 2025-01-01 2025-12-31 08093593 core:CurrentFinancialInstruments 2025-01-01 2025-12-31 08093593 core:Non-currentFinancialInstruments 2025-01-01 2025-12-31 08093593 1 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure

Company No: 08093593 (England and Wales)

NUNABIO LIMITED

Unaudited Financial Statements
For the financial year ended 31 December 2025
Pages for filing with the registrar

NUNABIO LIMITED

Unaudited Financial Statements

For the financial year ended 31 December 2025

Contents

NUNABIO LIMITED

COMPANY INFORMATION

For the financial year ended 31 December 2025
NUNABIO LIMITED

COMPANY INFORMATION (continued)

For the financial year ended 31 December 2025
DIRECTORS Susan Jane Bell (Appointed 19 November 2025)
Dr Glenn Crocker
Dr Joseph Henry Hedley
Martlet Capital Directors Limited (Resigned 20 August 2025)
Iain Alasdair Keith Moodie (Appointed 19 November 2025)
Dr Andrew Robert Pike (Resigned 20 August 2025)
Rebecca Jane Roberts (Appointed 20 August 2025)
Carl Andrew Sterritt (Resigned 29 October 2025)
Dr Eimer Mary Tuite (Resigned 20 August 2025)
Christopher Mark Wheatcroft (Resigned 20 August 2025)
SECRETARY Muckle Secretary Limited
REGISTERED OFFICE Time Central
32 Gallowgate
Newcastle Upon Tyne
NE1 4BF
United Kingdom
COMPANY NUMBER 08093593 (England and Wales)
ACCOUNTANT S&W Partners Newcastle Limited
17 Queens Lane
Newcastle
NE1 1RN
NUNABIO LIMITED

BALANCE SHEET

As at 31 December 2025
NUNABIO LIMITED

BALANCE SHEET (continued)

As at 31 December 2025
Note 2025 2024
£ £
Fixed assets
Intangible assets 3 114,348 83,823
Tangible assets 4 803,654 972,172
918,002 1,055,995
Current assets
Stocks 52,379 0
Debtors 5 369,728 418,472
Cash at bank and in hand 2,030,246 481,981
2,452,353 900,453
Creditors: amounts falling due within one year 6 ( 805,063) ( 876,288)
Net current assets 1,647,290 24,165
Total assets less current liabilities 2,565,292 1,080,160
Creditors: amounts falling due after more than one year 7 ( 41,699) ( 1,483,197)
Net assets/(liabilities) 2,523,593 ( 403,037)
Capital and reserves
Called-up share capital 11,438 6,514
Share premium account 6,871,413 2,095,853
Profit and loss account ( 4,359,258 ) ( 2,505,404 )
Total shareholders' funds/(deficit) 2,523,593 ( 403,037)

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The financial statements of NunaBio Limited (registered number: 08093593) were approved and authorised for issue by the Board of Directors on 23 April 2026. They were signed on its behalf by:

Susan Jane Bell
Director
NUNABIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
NUNABIO LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 December 2025
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

NunaBio Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Time Central, 32 Gallowgate, Newcastle Upon Tyne, NE1 4BF, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with ‘The Financial Reporting Standard applicable in the UK and the Republic of Ireland’ issued by the Financial Reporting Council, including Section 1A of Financial Reporting Standard 102 (FRS102), and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The functional currency of NunaBio Limited is considered to be pounds sterling because that is the currency of the primary economic environment in which the Company operates.

These financial statements are separate financial statements.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Profit and Loss Account in the period in which they arise on monetary items.

Turnover

Turnover is stated net of VAT and trade discounts and is recognised when the significant risks and rewards are considered to have been transferred to the buyer. Turnover from the sale of goods is recognised when the goods are physically delivered to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on enacted or substantively enacted tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment.

Other intangible assets 10 years straight line
Trademarks, patents and licences

Separately acquired patents and trademarks are included at cost. Provision is made for any impairment.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc. 20 - 33 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Balance Sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

2. Employees

2025 2024
Number Number
Monthly average number of persons employed by the Company during the year, including directors 18 17

3. Intangible assets

Other intangible assets Total
£ £
Cost
At 01 January 2025 83,823 83,823
Additions 41,197 41,197
At 31 December 2025 125,020 125,020
Accumulated amortisation
At 01 January 2025 0 0
Charge for the financial year 10,672 10,672
At 31 December 2025 10,672 10,672
Net book value
At 31 December 2025 114,348 114,348
At 31 December 2024 83,823 83,823

4. Tangible assets

Plant and machinery etc. Total
£ £
Cost
At 01 January 2025 1,203,350 1,203,350
Additions 35,876 35,876
At 31 December 2025 1,239,226 1,239,226
Accumulated depreciation
At 01 January 2025 231,178 231,178
Charge for the financial year 204,394 204,394
At 31 December 2025 435,572 435,572
Net book value
At 31 December 2025 803,654 803,654
At 31 December 2024 972,172 972,172

5. Debtors

2025 2024
£ £
Trade debtors 23,426 61,062
Corporation tax 205,926 105,012
Other debtors 140,376 252,398
369,728 418,472

6. Creditors: amounts falling due within one year

2025 2024
£ £
Trade creditors 118,975 136,904
Taxation and social security ( 181,568) 20,354
Obligations under finance leases and hire purchase contracts (secured) 141,509 141,509
Other creditors 726,147 577,521
805,063 876,288

The amounts due under finance leases and hire purchase contracts are secured against the assets to which they relate. The net book value of the fixed assets held under finance leases and hire purchase contracts was £356,469 (2024 - £445,586).

7. Creditors: amounts falling due after more than one year

2025 2024
£ £
Obligations under finance leases and hire purchase contracts (secured) 41,691 183,192
Other creditors 8 1,300,005
41,699 1,483,197

The amounts due under finance leases and hire purchase contracts are secured against the assets to which they relate. The net book value of the fixed assets held under finance leases and hire purchase contracts was £356,469 (2024 - £445,586).

8. Events after the Balance Sheet date

Since the year end the company has allotted the following shares:
- 4 February 2026, 5,149 A Ordinary shares at £9.71 each;
- 11 March 2026, 25,746 Ordinary shares for £9.71 each;
- 11 March 2026, 56,641 A Ordinary shares at £9.71 each;
- 1 May 2026, 25,747 A Ordinary shares at £9.71 each.